<DOC>
	<DOCNO>NCT01700920</DOCNO>
	<brief_summary>The purpose study analyze safety feasibility direct administration intrafemoral mesenchymal stem cell ( MSCs ) vitro expand autologous treatment patient femoral osteonecrosis .</brief_summary>
	<brief_title>PHASE II CLINICAL TRIAL Prospective , Open , Nonrandomized Treatment Osteonecrosis Femoral Head Administration Autologous Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>Age 18 70 year Clinical diagnosis imaging ( Rx NMR ) idiopathic osteonecrosis femoral head Stadiums &lt; IIIC ARCO rank Those investigator judgment good position tolerate procedure . Clinical criterion anesthetic contraindicate surgery ( eg ASA IVV ) Serious illness uncontrolled Pregnant woman Patients HIV infection + Acute infection ( previous 15 day ) chronic ( HIV ) Previous treatment osteonecrosis Active previous neoplastic disease ( last 5 year ) except patient undergo allogeneic haematopoietic progenitor complete remission 2 year transplantation . Lack informed consent revocation thereof .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteonecrosis femoral head</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Femoral Head</keyword>
</DOC>